Toll-like receptor (TLR) activation contributes to premalignant hematologic conditions, such as myelodysplastic syndromes (MDS). TRAF6, a TLR effector with ubiquitin (Ub) ligase activity, is overexpressed in MDS hematopoietic stem/progenitor cells (HSPCs). We found that TRAF6 overexpression in mouse HSPC results in impaired hematopoiesis and bone marrow failure. Using a global Ub screen, we identified hnRNPA1, an RNA-binding protein and auxiliary splicing factor, as a substrate of TRAF6. TRAF6 ubiquitination of hnRNPA1 regulated alternative splicing of Arhgap1, which resulted in activation of the GTP-binding Rho family protein Cdc42 and accounted for hematopoietic defects in TRAF6-expressing HSPCs. These results implicate Ub signaling in coordinating RNA processing by TLR pathways during an immune response and in premalignant hematologic diseases, such as MDS.
Toll-like receptor (TLR) signaling regulates myelopoiesis and innate immune responses, but chronic stimulation of TLR can lead to HSPC dysfunction 1 . Previous findings have described TLRs pathways in immune effector cells and, more recently, in coordinating RNA processing during hematopoietic differentiation 2, 3 . TLRs and their co-receptors are expressed on hematopoietic stem cells (HSCs) and are important for HSPC function 4 . Chronic TLR stimulation, such as by lipopolysaccharide (LPS) or during sepsis, induces durable changes in bone marrow (BM) physiology, including reduced HSC self-renewal, myeloid-biased differentiation and neutropenia 1 . Thus, it is not surprising that chronic TLR signaling has been implicated in mediating HSC defects and contributing to MDS [5] [6] [7] . MDS are clonal HSC disorders that are defined by cytopenia, myeloid cell dysplasia and ineffective hematopoiesis 8, 9 . Multiple genetic mechanisms contribute to TLR pathway activation in MDS 5, 6, [10] [11] [12] [13] , which converge on the central mediator of innate immune and TNF superfamily receptor signaling TRAF6. For example, deletion of miR-146a and/or TIFAB, two suppressors of TRAF6 that are associated with del(5q) MDS, result in TRAF6 overexpression 5, 14 . TRAF6 is an E3 ligase that synthesizes lysine (K) 63-linked Ub chains on substrates, leading to downstream pathway activation. Despite the association between chronic TLR signaling, diminished HSC fitness and MDS pathogenesis, the underlying cellular and molecular mechanisms remain unknown.
Using a hematopoietic-specific TRAF6 overexpression mouse model, we discovered a mechanism of RNA processing that involves ubiquitination of hnRNPA1, an RNA-binding protein, by TRAF6, which, under conditions of chronic TRAF6 signaling, altered RNA splicing and cell-intrinsic HSC defects associated with MDS.
RESULTS
Overexpression of TRAF6 impairs HSC function TRAF6 was overexpressed in ~40% of normal karyotype or del(5q) cells expressing the adhesion molecule CD34 from MDS patients as compared with CD34 + cells from healthy individuals ( Fig. 1a) . To model TRAF6 overexpression and genetically driven chronic TLR activation observed in MDS HSPCs, we generated transgenic mice that overexpress TRAF6 under the control of hematopoietic-specific Vav regulatory elements (called Vav-TRAF6 mice hereafter) 15, 16 ( Supplementary Fig. 1a-c) . To avoid supraphysiological expression of TRAF6, we selected transgenic mice in which TRAF6 expression was twofold higher than endogenous TRAF6 expression in wild-type HSPCs (LSK, Lineage − Sca1 + cKit + ) and was consistent with TRAF6 overexpression in MDS CD34 + cells (Fig. 1a) . Beginning at ~5 months, Vav-TRAF6 mice succumbed to a BM-failure-like disease, with 50% lethality beyond 15 months ( Fig. 1b) . Moribund Vav-TRAF6 mice developed leukopenia and anemia, neutrophil dysplasia, and reduced BM cellularity ( Fig. 1c-f) , and exhibited enlarged spleens resulting from extramedulary erythro-and myelopoiesis ( Supplementary  Fig. 1d,e) . Despite the BM failure, the numbers of CD34 − CD135 − LSK (LT-HSC), CD34 + CD135 − LSK (ST-HSC) and CD34 + CD135 + LSK (MPP) cells were elevated in the BM of Vav-TRAF6 mice compared with wild-type mice (Fig. 1g) . In methylcellulose assays, Vav-TRAF6 LSK cells formed fewer colonies than wild-type LSK cells (Fig. 1h) . (j) Colony formation in methylcellulose after serial replating of GFP-sorted Lin − BM cells (C57Bl/6) transduced with retroviral vectors (MSCV-IRES-GFP) encoding WT (n = 3) or an E3 ligase-mutant TRAF6 (TRAF6 C70A , n = 3). *P < 0.01. (k) Proportion of donor-derived (gated on CD45.2 + ;GFP + ) peripheral blood myeloid (CD11b + ) and lymphoid (CD3 + and B220 + ) cells were examined by flow cytometry for competitively transplanted GFP-sorted LSK BM cells (C57Bl/6) transduced with retroviral vectors encoding WT (n = 5) or an E3 ligase-mutant TRAF6 (TRAF6 C70A , n = 10) coexpressing GFP (MSCV-IRES-GFP 
A r t i c l e s
To assess the consequences of TRAF6 overexpression on HSC function in vivo, we competitively transplanted BM mononuclear cells or LT-HSC cells (CD34 − CD135 − LSK) from Vav-TRAF6 or wild-type donor mice with equal numbers of wild-type BM cells into lethally irradiated congenic wild-type recipients. The hematopoietic contribution of Vav-TRAF6 BM mononuclear cells to peripheral blood chimerism in primary recipients was moderately reduced compared with wild-type donor BM mononuclear cells ( Supplementary Fig. 2a,b) . Similarly, the hematopoietic contribution of Vav-TRAF6 LT-HSC cells to peripheral blood chimerism following serial transplantation of BM cells in secondary wild-type recipients was reduced compared with wild-type donor LT-HSC cells ( Supplementary Fig. 2a,b) . The reduced peripheral blood chimerism of Vav-TRAF6 BM-mononuclear-cell-or LT-HSC-derived progeny in recipient mice was mainly a result of diminished numbers of CD3 + and B220 + lymphoid cells as compared with lymphoid cells in recipient mice reconstituted with wild-type BM mononuclear cells or LT-HSC cells ( Supplementary  Fig. 2c ). However, BM chimersim of CD34 − CD135 − LSK (LT-HSC), CD34 + CD135 − LSK (ST-HSC) and CD34 + CD135 + LSK (MPP) cells was similar between Vav-TRAF6 and wild-type donor BM mononuclear cells or LT-HSC cells ( Supplementary Fig. 2d ) . We next examined mature immune cells in recipient mice that were competitively transplanted with BM mononuclear cells or LT-HSC cells (CD34 − CD135 − LSK) from Vav-TRAF6 or wild-type donor mice and equal numbers of wild-type BM cells. Peripheral blood CD11b + myeloid populations were expanded at the expense of CD3 + and B220 + lymphoid populations in CD45.2 + donor-derived Vav-TRAF6 BM mononuclear cells (from 27-41%) or LT-HSC cells (from 18-40%) when compared with either wild-type donor-derived BM mononuclear cells or LT-HSC cells, or with CD45.1 + competitorderived BM mononuclear cells from wild-type mice after 12 weeks ( Fig. 1i and Supplementary Fig. 2e) . These observations suggest that TRAF6 overexpression results in HSPC defects that are cell intrinsic and are associated with myeloid-biased differentiation.
To assess whether the Ub ligase activity of TRAF6 is required for the observed hematopoietic phenotype, we retrovirally expressed wild-type (TRAF6-LSK) and E3-ligase-defective TRAF6 (TRAF6-C70A-LSK) in BM LSK cells, which express low levels of endogenous Traf6, and examined hematopoietic progenitor colony formation in methylcellulose. TRAF6-LSK cells formed fewer total colonies following serial replating as compared with vector-transduced LSK cells ( Fig. 1j) .
In contrast, TRAF6-C70A-LSK cells formed similar number of colonies as vector-transduced LSK cells ( Fig. 1j) . We next examined the differentiation potential of TRAF6-LSK and TRAF6-C70A-LSK cells following competitive transplantation with an equal number of wild-type unfractionated BM cells into lethally irradiated congenic recipients. Peripheral blood CD11b + myeloid populations were significantly expanded at the expense of CD3 + and B220 + lymphoid populations in GFP + donor-derived TRAF6-LSK cells compared with donor-derived TRAF6-C70A-LSK or vector-transduced LSK cells after 8 weeks ( Fig. 1k) . Thus, HSPCs expressing the TRAF6 transgene were functionally impaired and showed a myeloid bias in vivo that was dependent on the Ub ligase activity of TRAF6.
RNA binding proteins are TRAF6 substrates
To determine the molecular pathways regulated by chronic TRAF6 overexpression, we performed microarray gene expression analysis in LSK cells sorted from the BM of 6-month-old Vav-TRAF6 and wildtype mice. 190 genes were differentially expressed in Vav-TRAF6 LSK cells compared with wild-type LSK cells ( Supplementary Table 1 and Supplementary Fig. 3a) . Gene set enrichment analysis revealed that Vav-TRAF6 LSK cells had downregulated genes that are characteristically expressed by quiescent LT-HSC cells 17 , such as Msi2, Esr1 and Bcl2l11, and showed upregulated expression profiles associated with mature hematopoietic cells and myeloid differentiation ( Supplementary Fig. 3b ), including Myc, Mpo, E2f8 and Ccr2 (Supplementary Fig. 3a) .
Although NF-κB and immune signaling is associated with normal TRAF6 function, gene expression profiles related to immune and inflammatory responses were not upregulated in Vav-TRAF6 LSK cells compared with wild-type LSK cells ( Supplementary Fig. 3b ). The amount of phosphorylated IKKβ was similar in Vav-TRAF6 and wild-type Lin − BM cells (data not shown), cytokines, such as interleukin 1a (IL-1a), IL-2, IL-3 and interferon-γ were comparable in the A r t i c l e s peripheral blood of Vav-TRAF6 and wild-type mice (data not shown), and inflammation or immune cell infiltration was not detected in moribund Vav-TRAF6 mice (data not shown), indicating that the hematopoietic phenotype in Vav-TRAF6 mice was not associated with activation of canonical NF-κB signaling and/or inflammation.
As such, we broadened our mechanistic investigation by searching for ubiquitinated substrates of TRAF6. For this, we performed global semiquantitative Ub capture proteomics in a TRAF6-overexpressing human leukemia cell line (TF1) that was engineered to express a doxycycline-inducible shRNA targeting TRAF6 ( Fig. 2a) . Ubiquitinated peptides immunoprecipitated from doxycyclinetreated TF1 cells to induce TRAF6 knockdown or from vehicletreated TF1 cells as controls were analyzed by mass spectrometry (Supplementary Fig. 4a ). The proteomic analysis identified 40 unique peptides from 29 proteins that were ubiquitinated in vehicletreated TF1 cells, but not in doxycycline-treated TRAF6-knockdown TF1 cells ( Fig. 2a, Supplementary Fig. 4b and Supplementary  Table 2 ). We then performed ubiquitiation assays with recombinant Ub-activating enzyme E1 (UBE1), E2 ubiquitin conjugating enzyme Ubc13 (UBE2N/UBE2V1), TRAF6 and Ub with the 29 putative protein substrates. We found that 11 of the 29 candidate proteins, hnRNPA1, MATR3, RPL3, RPS2, RPS20, RPS27A, HIST2H2BE, YWHAQ, MPP1, GART and PFN1, were ubiquitinated by TRAF6 in at least one replicate assay ( Fig. 2a and Supplementary Table 2 ). Gene ontology analysis indicated that 6 of the 11 TRAF6 substrates, hnRNPA1, MATR3, RPL3, RPS2, RPS20 and RPS27A, represented RNA-binding proteins ( Fig. 2a and Supplementary Table 2 ). Thus, we conclude that TRAF6 overexpression results in transcriptional changes and ubiquitination of RNA-binding proteins in HSPCs.
TRAF6 regulates RNA splicing via hnRNPA1
RNA-binding proteins have pleotropic effects on RNA stability, splicing and translation. To explore whether ubiquitination of RNAbinding proteins by TRAF6 results in altered RNA splicing, we performed a microarray exon expression analysis in LSK cells sorted from Vav-TRAF6 and wild-type mice. Two splicing metrics (splicing index and finding isoforms using robust multichip analysis, FIRMA), which calculate the relative expression of individual exons normalized to all exons in the corresponding gene 18, 19 , were implemented. We found that 1,316 genes exhibited changes in exon usage in Vav-TRAF6 LSK 
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Ub-hnRNPA1/ hnRNPA1: A r t i c l e s mice as compared with wild-type LSK mice (n = 521 exons using the splicing index; n = 1,919 exons using the FIRMA index; Fig. 2b and Supplementary Table 3 ). A subset of exons with altered usage in Vav-TRAF6 LSK was validated by RT-PCR. Among the ten exons selected, six were alternatively spliced in independent cohorts of Vav-TRAF6 LSK cells as compared with wild-type LSK cells: Mllt1 exon 2, Cep164 exon 7, Mtmr14 exon 18, Slmap exon 10, Sema4g exon 13 and Arhgap1 exon 2 ( Supplementary Fig. 5) .
To identify the mechanistic link between the ubiquitinated RNAbinding proteins and altered RNA exon usage in Vav-TRAF6 HSPCs, we performed RNA-binding motif and RNA-splicing pattern-enrichment analyses of alternatively spliced cassette exons in sorted Vav-TRAF6 LSK cells. For the motif-enrichment analysis, we examined RNAbinding models in the form of position frequency matrix motifs in the CisBP-RNA database to identify over-representation of RNA-protein binding sites in alternatively spliced cassette exons in Vav-TRAF6 LSK cells 20 . Significant enrichment of binding motifs for ELAV1/2/3/4, SRSF7, hnRNPA1, ZFP36 and snRNPA/B2 were found in the alternatively spliced exon sequences in Vav-TRAF6 LSK cells as compared with wild-type LSK cells ( Fig. 2c and Supplementary  Table 4 ). These findings were independently confirmed using a hypergeometric test, which measures consensus-based binding site enrichment (data not shown).
We next performed an RNA splicing signature analysis to compare exon-usage patterns of Vav-TRAF6 LSK cells with the RNA exon splicing patterns associated with RNA-binding proteins from published data sets. Exon-usage patterns associated with 11 RNA-binding proteins, namely RBM4, Fus2, Mbnl2, PTB, Nova1/2, Ddx5, hnRNPA1, Musashi2, Rbfox1, PRMT6 and Mbnl1 were significantly enriched in Vav-TRAF6 LSK cells compared with wild-type LSK cells ( Fig. 2d) . hnRNPA1 emerged as the only RNAbinding protein that was ubiquitinated by TRAF6 whose binding and an E3 ligase mutant (C70A; n = 5) TRAF6. Summary of Arhgap1 exon 2 exclusion from the minigene was calculated based on the short isoform as a percentage of the short and long isoforms is shown above from two independent experiments. *P = 0.03. (i) RT-PCR analysis of a minigene plasmid containing the Arhgap1 cassette exon 2 (using primers flanking exon 2, as depicted in the schematic on the left) in HEK293-Arhgap1exon2 cells transfected with TRAF6 and hnRNPA1 (WT and lysine mutants). Summary of Arhgap1 exon 2 exclusion from the minigene was calculated based on the short isoform as a percentage of the short and long isoforms is shown above from two independent experiments (n = 2 per group). Vec, vector; A1 WT , hnRNPA1 WT; A1 K3R , hnRNPA1 with K3R mutation; A1 K-R , hnRNPA1 with mutation of all lysines in the first RNA recognition motif. *P < 0.01, **P = 0.003. (j) qRT-PCR of Arhgap1 cassette exon 2 expressed from the minigene plasmid following RNA immunoprecipitation of Myc-hnRNPA1 in HEK293-Arhgap1exon2 cells transfected with Myc-hnRNPA1 (WT and K-R) and TRAF6. Shown is the average of two independent experiments (n = 2 per group). *P < 0.01. Data are from two experiments (e-j; means and s.e.m.).
motifs and global RNA splicing pattern were significantly enriched in LSK cells from Vav-TRAF6 mice. Thus, TRAF6 overexpression in HSPCs results in RNA splicing changes associated with hnRNPA1.
TRAF6 directly ubiquitinates hnRNPA1
Because hnRNPA1 has been implicated in human myeloid malignancies 21 , we selected it for further validation. Recombinant protein ubiquitination assays revealed that hnRNPA1 was ubiquitinated by TRAF6 to a similar magnitude as TAK1, a known TRAF6 substrate 22 (Fig. 3a) , indicating that hnRNPA1 is a direct substrate of TRAF6. Doxycycline-treated TRAF6 knockdown TF1 cells showed reduced hnRNPA1 ubiquitination compared with vehicle-treated TF1 cells ( Supplementary Fig. 4c) . Conversely, transfection of TRAF6 in HEK293 cells resulted in increased hnRNPA1 ubiquitination in the presence of wild-type Ub or Ub that only forms K63 linkages (Ub K63 ) as compared with HEK293 cells transfected with empty vector ( Fig. 3b and Supplementary Fig. 4d) . In contrast, expression of TRAF6 together with Ub that only forms K48-linkages (Ub K48 ) did not result in hnRNPA1 ubiquitination in HEK293 cells ( Fig. 3b) .
Compared with wild-type TRAF6, transfection of TRAF6-C70A in HEK293 cells did not result in ubiquitination of hnRNPA1 ( Fig. 3c) , indicating that the E3 ligase domain of TRAF6 is required for hnRNPA1 ubiquitination.
Our proteomic analyses revealed that hnRNPA1 was ubiquitinated on Lys3 (K3) ( Fig. 3d) , which is adjacent to the first RNA-recognition motif (RRM1) of hnRNPA1 (ref. 23 ). To determine whether hnRNPA1 RRM1 is ubiquitinated by TRAF6, we transfected TRAF6 with a mutant hnRNPA1 protein, in which Lys3 was substituted for arginine (hnRNPA1 K3R ) in HEK293 cells. Compared with wild-type hnRNPA1, ubiquitination of hnRNPA1 K3R by TRAF6 was modestly reduced ( Fig. 3d ), suggesting that additional Lys residues in hnRNPA1 can be ubiquitinated by TRAF6. Because ubiquitination of a substrate motif can be promiscuous, resulting in modification of adjacent Lys residues, we also mutated the five lysine residues in RRM1 adjacent to Lys3 (referred to as hnRNPA1 K-R hereafter). Transfection of TRAF6 with hnRNPA1 K-R in HEK293 cells resulted in a further reduction in hnRNPA1 ubiquitination as compared with ubiquitination of wild-type hnRNPA1 or hnRNPA1 K3R by TRAF6 ( Fig. 3d) , indicating that hnRNPA1 ubiquitination by TRAF6 primarily occurs at RRM1. We next examined the ubiquitination of hnRNPA1 by TRAF6 in primary hematopoietic BM cells. Immunoprecipitation of endogenous hnRNPA1 revealed that ubiquitination of hnRNPA1 was increased in Vav-TRAF6 BM mononuclear cells and in LPS-stimulated BM mononuclear cells as compared with wild-type BM mononuclear cells (Fig. 4a) . We next used shRNAs to knock down hnRNPA1 in wild-type and Vav-TRAF6 Lin − or LSK BM cells (Fig. 4b) . Knockdown of hnRNPA1 in Vav-TRAF6 Lin − BM cells (shA1-Vav-TRAF6) resulted in modestly increased total colony formation after serial replating as compared with Vav-TRAF6 Lin − BM cells expressing a non-targeting shRNA (shCtl-Vav-TRAF6) (Fig. 4c) . We then competitively transplanted shA1 or shCtl Vav-TRAF6 and wild-type LSK BM cells with wild-type BM mononuclear cells into lethally irradiated wild-type mice. shA1-Vav-TRAF6 LSK BM cells showed improved engraftment of peripheral blood CD45.2 + GFP + cells from 0.3% to 1.6% as compared with shCtl-Vav-TRAF6 LSK BM cells, whereas shA1-wild-type LSK BM cells showed reduced engraftment as compared with shCtl-wild-type LSK BM cells (Fig. 4d) . These findings suggest that hnRNPA1 was ubiquitinated by TRAF6, and this interaction is involved in the hematopoietic phenotype of Vav-TRAF6 mice.
TRAF6 induces splicing of Arhgap1 RNA hnRNPA1 regulates RNA splicing by directly binding RNA consensus sites [24] [25] [26] or indirectly through protein-RNA interactions 27 . To identify alternatively spliced genes implicated in the hematopoietic phenotype of Vav-TRAF6 mice, we focused on the most significantly altered exons in Vav-TRAF6 LSK cells, as revealed by the exon expression analysis. The top genes with differential exon usage included Flna, Il18rap, Arhgap1, Mcm6, Itpr1, Laptm5, Celf1 and Fbxw2 ( Fig. 5a and Supplementary Table 3 ). Arhgap1 (or Cdc42GAP), an inhibitor of Cdc42 by hydrolyzing GTP, was previously implicated in LT-HSC self-renewal and differentiation [28] [29] [30] , and as such emerged as the most relevant candidate. Exon 2 of Arhgap1 was excluded in Vav-TRAF6 LSK cells, but not wild-type LSK cells (Fig. 5b) . RT-PCR using primers flanking Arhgap1 exon 2 and Sanger sequencing showed exclusion of exon 2 in Vav-TRAF6 Lin − BM cells and in LPS-stimulated wild-type Lin − BM cells (Fig. 5c,d) . To establish whether hnRNPA1 is required for TRAF6-induced exclusion of Arhgap1 exon 2, we transduced Vav-TRAF6 or wild-type Lin − BM cells with hnRNPA1 shRNA (shA1) or a non-targeting shRNA (shCtl). Knockdown of hnRNPA1 in Vav-TRAF6 Lin − BM cells significantly reduced Arhgap1 exon 2 exclusion as compared with sh-Ctl-Vav-TRAF6 Lin − BM cells (Fig. 5e) .
We also investigated Arhgap1 exon 2 exclusion in wild-type and Traf6 −/− Lin − BM cells following LPS stimulation. LPS treatment resulted in exclusion of Arhgap1 exon 2 in wild-type Lin − BM cells, but not in Traf6 −/− Lin − BM cells ( Fig. 5f ), suggesting that Arghap1 exon 2 exclusion requires TRAF6.
To gain further insight into the regulation of Arhgap1 exon 2 exclusion, we generated an Arhgap1 exon 2 cassette splicing reporter in HEK293 cells (HEK293-Arhgap1exon2) 31 . Arhgap1 exon 2 or the A r t i c l e s flanking introns did not contain a conserved hnRNPA1 RNA-binding motif (data not shown). However, transfection of hnRNPA1 into HEK293-Arhgap1exon2 cells resulted in exclusion of Arhgap1 exon 2 from the splicing reporter as compared with vector-transfected HEK293-Arhgap1exon2 cells (Fig. 5g) . In addition, transfection of TRAF6, but not of the E3 ligase-defective TRAF6-C70A, into HEK293-Arhgap1exon2 cells led to the exclusion of Arhgap1 exon 2 from the splicing reporter ( Fig. 5h) . To investigate whether TRAF6mediated exon skipping occurs through an hnRNPA1 ubiquitination-dependent mechanism, we co-expressed TRAF6 and either hnRNPA1, hnRNPA1 K3R or hnRNPA1 K-R in HEK293-Arhgap1exon2 cells. Expression of TRAF6 and hnRNPA1 resulted in increased exclusion of Arhgap1 exon 2 from the splicing reporter as compared with TRAF6 alone (Fig. 5i) , whereas expression of hnRNPA1 K-R , and to a lesser extent hnRNPA1 K3R , were not as effective as hnRNPA1 at inducing Arhgap1 exon 2 exclusion (Fig. 5i) . To evaluate whether ubiquitination of hnRNPA1 affected its binding to Arhgap1 exon 2, we performed RNA immunoprecipitation for Arhgap1 exon 2 in HEK293-Arhgap1exon2 cells transfected with TRAF6 and either hnRNPA1 or hnRNPA1 K-R . Transfection of TRAF6 and hnRNPA1 resulted in increased binding of hnRNPA1 to Arhgap1 cassette exon 2 by fourfold compared with transfection of only hnRNPA1 (Fig. 5j) .
In contrast, transfection of TRAF6 and hnRNPA1 K-R resulted in increased binding of hnRNPA1 K-R to Arhgap1 cassette exon 2 by only twofold compared with hnRNPA1 alone (Fig. 5j) . These data suggest that ubiquitination of Lys residues in the RRM1 of hnRNPA1 by TRAF6 enhance the binding to Arhgap1 cassette exon 2, resulting in exon exclusion.
Exclusion of exon 2 results in reduced Arhgap1 protein
Arhgap1 contains a conventional open-reading frame (ORF) initiated in exon 4 and an upstream ORF (uORF) in exon 1. The uORF is terminated by a stop codon in exon 2 (Fig. 6a) . To examine the consequences of exon 2 exclusion on Arhgap1 protein, we transfected hemagglutinin (HA)-tagged Arhgap1 cDNAs with the Arhgap1 5′ UTR (WT-UTR-Arhgap1) or without the Arhgap1 5′ UTR (∆UTR-Arhgap1) in HEK293 cells and evaluated protein expression by immunoblotting with Arhgap1 or HA antibodies. Transfection of ∆UTR-Arhgap1 or WT-UTR-Arhgap1 resulted in translation of Arhgap1 from the conventional ORF (Arhgap1 ORF), as shown by the 50-kDa Arhgap1 protein (Fig. 6a) . In contrast, deletion of exon 2 in the 5′ UTR (∆Exon2-UTR-Arhgap1) resulted in an absence of Arhgap1 protein expression from the conventional Arhgap1 ORF (Fig. 6a) . Moreover, transfection of ∆Exon2-UTR-Arhgap1 resulted in translation from the uORF and generated a chimeric Arghap1 protein with 40 additional N-terminal amino acids (Fig. 6a) . Mutation of the stop codon in exon 2 (TAA:GCC-UTR-Arhgap1) resulted in reduced expression of Arhgap1 protein from the conventional ORF ( Fig. 6a) and utilization of the uORF to produce a chimeric Arhgap1 protein with 65 additional N-terminal amino acids (Fig. 6a) . These findings indicate A r t i c l e s that exclusion of Arhgap1 exon 2 prevents translation of Arhgap1 from the ORF and induces alternative ORF usage. We next examined the consequences of exon 2 exclusion on Arhgap1 RNA and protein expression in Vav-TRAF6 LSK. As assessed by microarray and qRT-PCR, Arhgap1 mRNA expression was comparable in wild-type and Vav-TRAF6 LSK cells (Fig. 6b) . In wild-type Lin − BM cells, Arhgap1 protein was expressed from the conventional ORF as determined by immunoblotting (Fig. 6c) . In contrast, Arhgap1 protein expression from the conventional ORF was reduced in Vav-TRAF6 as compared with wild-type Lin − BM cells (Fig. 6c,d) , suggesting that exon 2 is required for proper Arhgap1 protein expression. The chimeric Arhgap1 protein derived from the uORF was not detectable in primary Vav-TRAF6 Lin − BM cells (Fig. 6c) , for reasons that remain unclear. However, we observed that Cdc42-GTP expression was significantly higher in Vav-TRAF6 Lin − BM cells than in wild-type Lin − BM cells (Fig. 6c,d) , suggesting increased Cdc42 activation. These findings indicate that TRAF6 overexpression induces exclusion of Arhgap1 exon 2, leading to diminished Arhgap1 protein expression and Cdc42 activation in HSPCs.
The hematologic phenotype and reduced Arhgap1 protein expression in Vav-TRAF6 mice was reminiscent of the phenotype of Arhgap1-deficient mice, which exhibit increased Cdc42 activity, impaired hematopoiesis and myeloid-biased differentiation [28] [29] [30] . Similar with Vav-TRAF6 mice, Arhgap1 +/− neutrophils exhibited a dysplastic phenotype (Supplementary Fig. 6) . To investigate whether Cdc42 activation contributes causally to the hematopoietic defects observed in Vav-TRAF6 mice, we used the selective inhibitor CASIN to inhibit Cdc42 in HSCs 28, 32 . We transplanted 200 LT-HSC (CD34 − CD135 − LSK) sorted from CD45.2 + Vav-TRAF6 mice directly with 2 × 10 5 wild-type CD45.1 + BM cells into irradiated wild-type congenic mice, or we transplanted them after treatment with CASIN (or control DMSO) for 24 h and with 2 × 10 5 wildtype CD45.1 BM cells into irradiated wild-type mice. Vav-TRAF6 LT-HSC (transplanted either directly or after overnight culture in media containing DMSO) generated ~65% CD11b + myeloid cells of the CD45.2 + donor-derived peripheral blood, as compared with ~35% wild-type CD11b + cells, by 8 weeks post transplantation (Fig. 7a,b) . However, CASIN-treated Vav-TRAF6 LT-HSCs formed fewer CD11b + myeloid cells among donor (CD45.2 + )-derived peripheral blood, from 37% to 66%, compared with DMSO-treated Vav-TRAF6 LT-HSC after 8 weeks (Fig. 7a,b) . Reduced chimerism from CASIN-treatment of Vav-TRAF6 LT-HSC resulted from fewer CD45.2 + -donor CD11b + myeloid cells and increased CD3 + and B220 + lymphoid cells relative to wild-type CD45.1 + myeloid and lymphoid cells in peripheral A r t i c l e s blood (Fig. 7c) . In addition, intraperitoneal injection of CASIN or PBS as a control for 16 continuous days after adoptive transfer of 200 Vav-TRAF6 LT-HSC and 2 × 10 5 wild-type BM competitor cells into lethally irradiated wild-type mice resulted in an expansion of Vav-TRAF6 CD45.2 + CD11b + myeloid cells by ~50% as compared with wild-type CD45.1 + CD11b + over 4 weeks in PBS-treated chimeric mice, whereas Vav-TRAF6 CD45.2 + CD11b + frequencies did not increase over 4 weeks in CASIN-treated chimeras (Fig. 7d) . These findings suggest that Cdc42 activation can cause the myeloid bias observed in the Vav-TRAF6 mice.
Cdc42 activation is associated with human MDS Next, we assessed alternative RNA splicing changes of Arhgap family members in publically available data sets from human MDS-AML samples and cell lines [33] [34] [35] . We identified significant RNA splicing alterations of ARHGAP11b, ARHGAP17, ARHGAP19 and ARHGAP22 in MDS and AML BM CD34 + cells and cell lines. Among these, ARHGAP17 underwent exclusion of exon 18 in human monocytic leukemic cells (THP1) following LPS stimulation 34 and in an MDS-patient-derived human cell line (MDSL) ( Fig. 8a and Supplementary Fig. 7a) . To establish the contribution of TRAF6 to ARHGAP17 exon 18 exclusion, we transduced MDSL cells with shR-NAs targeting TRAF6 (shTRAF6-MDSL) or a non-targeting shRNA (shCtl-MDSL). RT-PCR using primers flanking exons 17 and 18 or exon 18 of ARHGAP17 revealed that shTRAF6-MDSL had restored expression of the ARHGAP17 exon 17, 18 and 19 cassette compared with shCtl-MDSL cells (Fig. 8a,b) . In human MDS BM cells, exclusion of exon 18 resulted in premature termination of ARHGAP17 protein (Supplementary Fig. 7a ), whereas inclusion of ARHGAP17 exon 18 in shTRAF6-MDSL cells resulted in restored ARHGAP17 protein expression ( Fig. 8b) , indicating that exon 18 is essential for proper ARHGAP17 protein expression. The splice junctions between exons 16-19 and between exons 17 and 19 of ARHGAP17 in MDSL cells were independently confirmed by Sanger sequencing (Fig. 8c) . As we observed in shTRAF6-MDSL cells, shRNA-mediated knockdown of hnRNPA1 in MDSL cells (shA1-MDSL) resulted in restoration of full-length ARHGAP17 mRNA and expression of ARHGAP17 protein (Supplementary Fig. 7b-d) .
We next determined whether ARHGAP17 exon 18 exclusion is associated with TRAF6 overexpression in primary human MDS. RT-PCR analysis of BM mononuclear cells revealed that increased TRAF6 expression correlated with exclusion of ARHGAP17 exon 18 in MDS patients and normal BM cells (Fig. 8d) . In addition, we examined TRAF6 expression and ARHGAP17 exon 18 exclusion by qRT-PCR in a larger cohort of primary MDS and AML BM mononuclear cells. Using primers aligning to the splice junction of exons 17-19 of ARHGAP17, we found that increased TRAF6 mRNA positively correlated with exclusion of exon 18 from ARHGAP17 in MDS and AML samples (Fig. 8e) , indicating that TRAF6 overexpression is associated with alternative RNA splicing of ARHGAP17. Because ARHGAP17 is a negative regulator of Cdc42 (ref. 36 ), we evaluated the amount of Cdc42-GTP in MDSL cells following TRAF6 knockdown. Cdc42-GTP was significantly lower in shTRAF6-MDSL cells than in shCtl-MDSL cells (Fig. 8f) , indicating that restored ARHGAP17 protein expression suppresses Cdc42 activity. In contrast, knockdown of ARHGAP17 in MDSL cells with a GAP17-shRNA resulted in increased Cdc42-GTP relative to MDSL cells expressing a non-targeting shRNA (shCtl-MDSL) (Fig. 8g) . Moreover, transduction of GAP17-shRNA in primary human CD34 + cells resulted in reduced total colony formation as compared with non-targeting shRNA (shCtl) CD34 + cells (Fig. 8h) . As such, lower ARHGAP17 expression, as observed following exclusion of exon 18 in MDS, and increased Cdc42 activation impair human CD34 + HSPC function. Taken together, our data indicate that alternative splicing of Arhgap proteins contributes to increased Cdc42 activation and aberrant hematopoiesis following activation of TRAF6 in MDS (Supplementary Fig. 7e) .
DISCUSSION
Our results show that TRAF6 affects HSPC function by regulating exon specification through ubiquitination of the RNA-binding protein hnRNPA1 and provide insight into how hematopoietic cells regulate RNA isoform expression during TLR signaling. We identified several hnRNP family members as being potential TRAF6 substrates. Thus, it is possible that TRAF6 signaling downstream of TLR, IL-1R and/or TNF superfamily of receptors coordinates RNA processing via ubiquitination of multiple auxiliary RNA splicing factors. Our mechanistic interrogation revealed that, in the presence of TRAF6, hnRNPA1 induced exclusion of Arhgap1 exon 2. The precise mechanism by which ubiquitination of hnRNPA1 controls Arhgap1 exon 2 splicing or globally regulates RNA processing was not clear, as hnRNPs can couple RNA splicing with nuclear export, and/or affect RNA splicing directly by binding RNA response elements, or in trans through protein interactions with other RNA splicing proteins 37 . Multiple independent genetic alterations and molecular mechanisms have been reported that suggest that chronic immune-related signaling contributes to the pathogenesis of MDS. These MDS-associated alterations converge on activating the TRAF6 signaling complex 38 . Chronic inflammation mediates pleiotropic effects on hematopoiesis by cell-autonomous and non-autonomous mechanisms. Moreover, chronic immune signaling has durable and irreversible effects on HSC function 1, 39, 40 . Although an inflammatory BM milieu and/or altered immune effector cells may contribute to HSC dysfunction and MDS, our results clearly demonstrate that TRAF6 induced cellintrinsic HSC defects. TRAF6 mediated RNA splicing of Arhgap1 and activation of the small GTPase Cdc42, which conferred at least part of the hematopoietic phenotype in Vav-TRAF6 mice. Mice with constitutively elevated Cdc42 activity, as a consequence of Arhgap1 deletion, displayed premature aging phenotypes in multiple tissues, including HSCs 41 . Innate immune signaling and inflammation are also thought to be implicated in aged HSCs 1, 42 , which would provide a mechanistic explanation for Cdc42 activation in aged HSC. In summary, we found that RNA processing in hematopoietic cells is regulated by TRAF6-mediated ubiquitination of an RNA-binding protein, hnRNPA1, and that chronic innate immune signaling via TRAF6 impairs HSPC function and contributes to the pathogenesis of MDS through altered splicing of HSC-requisite genes.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Mice and primary murine bone marrow cell culture. Generation of the Vav-TRAF6 mice was accomplished by cloning a flag tagged human TRAF6 cDNA downstream of the Vav promoter, followed by pronuclear microinjection of linearized Vav-FLAG-TRAF6 fragment into fertilized eggs. Mouse and human TRAF6 protein have 92% amino acid identity and functional conservation. The eggs were then transferred into pseudopregnant FVB/NJ mice. Vav-TRAF6 mice were also subsequently backcrossed onto C57Bl/6 genetic background. TRAF6 fl/fl mice (C57Bl/6) were a kind gift from Y. Choi (University of Pennsylvania) 43 
Retroviral expression of TRAF6 in mouse HSPC BM cells.
For WT and E3 ligase-defective (C70A) TRAF6 overexpression, HSPC-enriched LSK or Lin-BM cells were obtained from C57Bl/6 or Traf6 fl/fl ;Vav-Cre mice, and then infected with retroviral vectors (co-expressing GFP, see plasmid description below). Cells were flow-sorted for GFP + cells after 72 h and then examined for colony formation in methylcellulose or for PB reconstitution in lethally irradiated mice (CD45.1 + B6.SJL Ptprca Pep3b/BoyJ ; 6-10 weeks of age).
Hematological and histological analysis. Peripheral blood was collected by cheek piercing or cardiac puncture. Blood counts were measured with a hemacytometer (HEMAVET). Spleens and tibias were fixed with 4% PFA, sectioned and stained with H&E for histopathological analysis. Cytospin was performed with 2 × 10 5 BM cells. Blood smear and cytospin were stained with Wright-Giemsa for morphological analysis. Dysplastic cells were evaluated on at least 100 cells per mouse and confirmed by a pathologist. For neutrophils with Pelger-Huet anomalies, hyposegmentation as a bilobed nucleus was present.
Exon array analysis. HSPC-enriched LSK cells were sorted from WT (FVB/NJ) and Vav-TRAF6 mice (FVB/NJ) (6 months of age). Total RNA was extracted from LSK cells and purified with Quick-RNA MiniPrep Kit (Zymo Research). RNA quality was tested using the Agilent Bioanalyzer 2100 (Hewelett Packard). Total RNA was reverse transcribed and labeled, and hybridized onto GeneChip Mouse Exon 1.0 ST Array (Affymetrix). Scanning was performed with the Affymetrix GeneChip Scanner 3000 7G and evaluated with the Genechip Operating Software (Affymetrix). Data mining was performed with GeneSpring software (Agilent). Gene set enrichment analysis was performed on a JAVA-based data set supported by the Broad Institute.
ToppGene analysis (http://toppgene.cchmc.org) was performed to identify enriched pathways.
Exon usage pattern analysis. Detection of alternative splicing events between pairs of biological groups was performed with AltAnalyze (v. 2.0.6) 44 , a Pythonbased program. Briefly, a 'robust multi-chip analysis' (RMA) summarization on the selected CEL files was initially generated, and only the probesets that can be aligned to a single ENSEMBL gene were included. This step generated the gene-level expression statistics and annotations for each ENSEMBL gene and each biological comparison group. The probeset-level expression values were further filtered based on DABG P-values cutoff and absolute expression levels for each biological comparison group. Based on these values, the standard alternative exon statistics (that is, FIRMA, MiDAS P-value, normalized P-value) were computed for each analyzed probeset relative to the determined gene expression levels. For FIRMA analysis 19 , Affymetrix probe residuals for all probes associated with a gene (metaprobeset) were obtained by performing a second round of RMA summarization (using APT) for all probesets associated with AltAnalyze core probeset, "extended" probeset, or "full" probeset definitions. FIRMA scores for each probeset and sample were further summarized by AltAnalyze along user-defined biological groups and comparisons to obtain a FIRMA fold change and P-value (two-tailed t-test assuming unequal variance). We used the 0.05 as P-value threshold. CORE probesets were used to perform general alternative splicing analysis, but "extended" and "full" probesets were used to visualize the global missplicing patterns using a heatmap. Specifically, probe sets with the core annotation include all Affymetrix core probe sets that specifically overlap with a single ENSEMBL gene, along with any probe set that overlaps with an ENSEMBL or UCSC exon. For exon/intron splicing assay of WT and Vav-TRAF6 LSK cells, the parameters for AltAnalyze program were as follows: dabg (P < 0.05); raw expression threshold (1.0); alt exon fold variable (2.0); gene expression cutoff (3.0); P < 0.05. For FIRMA, the median of the residuals for each probe set for each array sample is compared to the median absolute deviation for all residuals and samples for the gene, as previously described 19, 44 . To study splicing patterns of LPS-treated and untreated THP-1 cells, Gene Expression Omnibus data set (GSE32141; Affymetrix HuEx1.0 ST exon array) was analyzed with the following parameters in AltAnalyze: dabg (P < 0.05); raw expression threshold (1.0), alt exon fold variable (2.0); gene_expression cutoff (3.0); P < 0.05. Details on the Splicing Index analysis are previously described 18 .
Splicing pattern enrichment analysis. Identification of alternative exons for 46 previously published splicing factor knockdown, overexpression or mutation data sets (mouse or human) was obtained using AltAnalyze, followed by overrepresentation analysis in GO-Elite (Supplementary Table 5 ). Enrichment Z scores for alternative exons from Vav-TRAF6 LSK among regulated exons from 46 evaluated splicing factors (siRNA, knockout, overexpression, mutation). Only results for splicing factors with at least 4 matching regulated exons in comparison to TRAF6-overexpression patterns are shown. Enrichment was performed using GO-Elite separately for upregulated (increased exon-inclusion) and downregulated (increased exon-exclusion) separately for the input exons and evaluated splicing factor regulated exons. Splicing-factors with at least ten exons regulated in common with the indicated splicing factor are shown. The splicing factor predicted expression (up or downregulated) is indicated based on expression of the enriched exons in Vav-TRAF6 LSK.
RNA binding protein site enrichment analysis. Exon and intron sequences were retrieved using R/Bioconductor's (http://www.bioconductor.org) BSgenome packages. All exons and flanking introns (with explicit start-end coordinates) defined in TXdb (for SpliceTrap) and EnsMart65 (for AltAnalyze) were used as search spaces to compute the total occurrence and location of each predicted binding site (see below). Entire exon blocks (merged Ensembl transcript models from AltAnalyze) were scanned, along with 5′ and 3′ intron region sequences (50nt, 500nt and full intron windows from adjacent splice sites). Exon-inclusion, exon-exclusion and combined differentially regulated probe sets (FIRMA) were scanned separately. Only the exons passing basal expression filters and having explicit start-end coordinates were considered for further analysis (219219 for human RNA-seq data, 261178 for mouse exon array data). To examine these exon and intron sequences for putative binding sites for specific RNA binding proteins (RBPs), we used a public library of 228 human RBP binding models in the form of position frequency matrix motifs obtained from the CisBP-RNA database 20 , and supplemented them with 12 additional motifs for hnRNP family members. This collection of binding models was used to create a custom motif library in the HOMER software package 45 . We then used the HOMER algorithm to systematically estimate the significance of the presence of matches to each motif in each input sequence set, scanning only the sense strand in the RNA sequences.
As a complementary approach, we employed a consensus-based binding site enrichment analysis, wherein regular expression pattern searches were determined for a given consensus site on skipped and non-skipped exon sequences. For hnRNPA1 binding motif enrichment analysis, human and mouse consensus binding sites (AGNUAGNN, GUAGUAGU, UAGGGA, UAGGGU) [24] [25] [26] were used. For exons containing binding site matches at multiple locations for a given consensus site, we counted multiple occurrences as "1" for our enrichment tests. Target exons were categorized into 4 groups: with binding site skipped; without binding site skipped; with binding site included; and without binding site included. Binding site enrichment was then performed using the hypergeometric test 46 .
For human AML, 179 patient (Level3) sample data sets were downloaded from TCGA website. 13 samples with high and 9 samples with low level of TRAF6 (in RPKM) were selected for splicing assay. Corresponding TCGA level-1 data (RNA-seq BAM files) were obtained through dbGaP (https://dbgap.ncbi. nlm.nih.gov) and CGHub UCSC (https://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE64542). Each BAM file was converted into two FASTQ files using PICARD's SamToFastq tool (v1.98) and used as inputs to SpliceTrap 47 . To quantify exon inclusion ratios based on paired-end reads using SpliceTrap (v0.90.5), each exon was analyzed with respect to adjacent exons flanking the middle spliced exons. The unpaired t-test was used in order to assess the difference of exon usage between these two groups. The exon inclusion ratio was defined as the expression level of the inclusion isoform divided by the total expression level of both isoforms (inclusion and skipped) derived from an exon trio. Inclusion ratio is used to separate constitutive exons (CS, inclusion ratio > 0.9) and cassette/alternative exons (CA, inclusion ratio < 0.9). Since SpliceTrap does not provide per-group analysis, we made arbitrary cutoff (>75% in each group) for exons of interest showing the consistent alternative splicing patterns. As above, hnRNPA1 motif enrichment was determined by the hypergeometric test.
TRAF6 ubiquitin substrate identification by subtractive proteomics.
Identification of ubiquitinated peptides was performed in accordance to the manufacturer recommendations (PTMScan Ubiquitin Proteomics System, Cell Signaling Technology). TF1 cells transduced with a doxycycline-inducible TRAF6 shRNA were grown in RPMI1640 supplemented with FBS and rhIL3. Cells were treated with or without doxycycline for 72 h. After treatment, cells were lysed in denaturing lysis buffer. Lysates were digested with trypsin followed by peptide desalting. Peptides were immunoprecipitated with αnti-diGly coupled to protein A agarose beads for 1 h at 4 °C. Eluted peptides were analyzed by LC-MS/MS on an ABSciex 5600 TripleTOF mass spectrometer coupled to an Eksigent nanoLC.ultra nanoflow HPLC system as described 48 . MS/MS spectra searches of the nano-LC-MS/MS data (*.wiff file) from the enriched diGly peptides were processed for protein identification using ProteinPilot TM software (version 4.2, revision 1297) supplied by ABSciex. The data were searched against a SwissProt database of Homo sapiens protein sequences with "Biological Modifications" (which included diGly) as a specified defaults in the ProteinPilot software. The resulting *.group file was then used to generate a spreadsheet as a peptide summary report. Peptides identified with a minimum of 99% confidence are reported. Data obtained from TRAF6-expressing (without doxycycline) and in TRAF6-depleted (with doxycycline) TF1 cells was used to generate a non-redundant list of diGly sites.
In vitro ubiquitination assay. Validation of hnRNPA1, TAK1, and Tubulin ubiquitination was performed in accordance with the manufacturer recommendations (E3 Substrate ID, LifeSensors, Inc). In vitro ubiquitin reconstitution assays were performed on two protein arrays (Invitrogen ProtoArray). Recombinant E1 (UBE1), E2 (UBE2N/UBE2V1), wild-type ubiquitin, and ATP were included in each reaction. One array also received a mix containing purified human TRAF6 protein. Arrays were visualized with Tandem Ubiquitin Binding Entities (TUBEs) and FK2 followed by the corresponding Cy-dye labeled secondary detection reagents. To calculate ubiquitination of hnRNPA1, TAK1, and Tubulin, median intensities subtracted from background intensities were used from biological replicates (F532 Median -B532 Median = ubiquitin intensity).
RNA immunoprecipitation. RNA immunoprecipitation was performed as previously described 49 . Briefly, HEK 293 cells were crosslinked with 1% formaldehyde. Crosslinking was stopped by the addition of 200 mM glycine. 500 µg protein lysate was precleared with protein G Dynabeads (Life Technologies, 10007D), and immunoprecipitation was performed with 10 µg of Myc antibody (Santa Cruz, sc-40) with rabbit IgG1 (Cell Signaling, 54153; negative control). RNA bound to the immunoprecipitated proteins was recovered by the treatment with proteinase K and DNase, and then measured with qRT-PCR. Primers to measure pre-mRNA are 5′-ATCTGAGAGAGTGGCTTTT TGC-3′ and 5′-CTGCTTCTGGTGCCTTCTG-3′.
Patient samples.
Informed consent was obtained according to protocols approved by the review boards of MD Anderson Cancer Center and Cleveland Clinic. Diagnoses were reviewed and adapted, when required, to WHO 2008 criteria. For qRT-PCR analysis of TRAF6 transcript and ARHGAP17 missplicing, BM aspirates were collected from 36 MDS/AML patients and 7 age-matched healthy controls ( Supplementary Table 6 ). RT-PCR analysis of ARHGAP17 splicing was performed on TRAF6 high and TRAF6 low MDS/AML patients (as determined by qRT-PCR and selected for > twofold or < onefold TRAF6 mRNA expression) and healthy controls.
Cell lines and CD34 + cells. TF1 and HEK293 cells were purchased from the American Type Culture Collection. MDSL was provided by K. Tohyama (Kawasaki Medical School). TF1 and MDSL cells were cultured in RPMI 1640 medium plus 10% FBS and 10 ng/ml human recombinant interleukin 3 (rhIL-3, 200-03, Peprotech). HEK293 cells were maintained in DMEM media with 10% FBS. Human CD34 + cord blood cells were prestimulated in StemSpan SFEM supplemented with recombinant human stem cell factor (rhSCF; 300-07, Peprotech), recombinant human Flt3 ligand (rhFL; 300-19, Peprotech), recombinant human thrombopoietin (rhTPO; 02522, PeproTech) at 100 ng/ml for 48 h before transduction, and then maintained in rhSCF, rhFL, rhTPO, rhIL-3, and recombinant human IL-6 (rh IL-6; 200-06, Peprotech) at 10 ng/ml.
Colony-forming assay.
Murine LSK or BM mononuclear cells (MNCs) were harvested from WT (FVB/NJ) and Vav-TRAF6 mice (FVB/NJ) (~4 months of age), and plated in methylcellulose (3434; Stemcell Technologies). Colonies were counted at 12-14 days after plating. For knockdown of mouse hnRNPA1, Lin − BM cells from WT (FVB/NJ) and Vav-TRAF6 mice were transduced with shRNA-expressing lentivirus, sorted for GFP + cells by FACS, and plated in methylcellulose (3434; Stemcell Technologies). In addition, Lin − BM cells from WT (C57Bl/6) mice were transduced with retrovirus encoding TRAF6 or ligase inactive TRAF6 C70A , and sorted for GFP + cells by FACS, and plated in methylcellulose (3434; Stemcell Technologies). For knockdown of human ARHGAP17, CD34 + cells were transduced with shRNA-expressing lentivirus, sorted for GFP + cells by FACS, and plated in methylcellulose (4434, Stemcell Technologies).
Flow cytometry. BM MNC were washed and incubated for 30 min with biotin conjugated lineage markers (CD11b, Gr1, Ter119, CD3, B220, Mouse Hematopoietic Lineage Biotin Panel, 88-7774-75, eBioscience), followed by staining with streptavidin APC-Cy7 (554063, BD Pharmingen), Sca-1 PE-cy7 (25-5981-82, eBioscience), c-Kit APC (17-1171-81, eBiosciences), CD34 FITC (11-0341-81, eBiosciences), CD135 (12-1351-81, eBiosciences). Long-term HSCs (LT-HSCs) were purified based on surface markers as Lin − Sca − 1 + c-Kit + CD34 − CD135 − . For colony forming assay using LSK cells, murine BM MNC were washed and incubated for 30 min with biotin conjugated lineage markers (CD11b, Gr1, Ter119, CD3, B220, Mouse Hematopoietic Lineage Biotin Panel, 88-7774-75, eBioscience), followed by staining streptavidin eFluor 450 (48-4317-82, eBioscience), Sca-1 PE (12-5981-82, eBioscience), c-Kit APC
